← FDA DRUG APPROVALS

FDA ANDA · ANDA078453

AMLODIPINE BESYLATE

Sponsor: ORBION PHARMS

APPLICATION
ANDA078453
TYPE
ANDA
ORIGINAL APPROVAL
2009-07-02
LATEST ACTION
2018-04-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 5MG BASE · TABLET · ORAL
AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 10MG BASE · TABLET · ORAL
AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 2.5MG BASE · TABLET · ORAL

Approval history

2018-04-25Labeling · Supplement 6 · standardAP
2018-04-25Labeling · Supplement 5 · standardAP
2015-10-07Labeling · Supplement 4 · standardAP
2014-10-26Labeling · Supplement 2AP
2014-10-26Labeling · Supplement 3 · standardAP
2011-08-29Labeling · Supplement 1AP
2009-07-02OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →